Date updated:02-23-2008
Summary of the bullish and bearish positions mentioned in the February 23rd, 2007 Barron's.

-
ANF
Abercrombie & Fit - $32.26
- 0.00%
- $31.84
The company's stock could top $100 within a year, climbing by a third. Abercrombie's new Gilly Hicks lingerie chain looks promising, joining the hugely popular Hollister.

-
CELG
Celgene Corporati - $44.28
- +3.94%
- $42.61
Celgene's earnings-growth pace could keep rising -- to 50% -- on more drug triumphs, as could the high (some say too high) 24 multiple on its stock. But at 54 now, it may be worth 20% more.

-
ZURN.VX
Zurich Finl Svcs - $203.50
- +2.57%
- $200.00
If Zurich Financial Services stays on course to deliver strong earnings and high returns on equity, its shares, now 317 Swiss francs, could rally 25% or more.

-
MRVL
Marvell Technolog - $11.16
- -8.00%
- $11.56
Marvell shares could double in two years if it fixes its options mess, controls costs and gets a 3G-capable chip to market.

-
DIS
Disney (walt) Co. - $25.13
- 0.00%
- $25.09
For the price of a Disney share, too, an investor effectively buys access to a braintrust probably unrivaled in American business. Apple's Steve Jobs, a Pixar founder, is Disney's largest shareholder, with 7% of the float. Fellow owner Warren Buffett no doubt picks up the phone for Iger. Procter & Gamble's former CEO, John Pepper, with all the consumer-product knowledge one could want, chairs Disney's board.

-
CROX
Crocs - $3.02
- -2.27%
- $3.01
We're neutral now, and think investors should cover their short positions and take a walk. The stock sells today for only nine times analysts' '08 earnings estimate of around $2.70 a share, and the shoes are still the rage among soccer moms and nurses, suggesting the stock might not drop much lower from here, at least in the near term.

-
WYE
Wyeth - $45.00
- 0.00%
- $44.91
In her estimation, Wyeth's stock price suggests that investors do not appreciate the value of these assets. At $40, Rubin contends, investors are effectively "getting the pipeline for free." Her analysis suggests that Wyeth's vaccines, biologics (biotechnology drugs) and OTC assets are worth about $35, or about 90% of the stock price. By 2012, Rubin expects biologics and vaccines to account for about 70% of Wyeth's earnings. She raised her investment rating on the stock to Overweight from Equal Weight, and upped her one-year price target to $48 from $46.
- Barron's Summary 02-23-2008's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Highbridge Statistical...
- 3. Joel Greenblatt
- 4. Amana Trust Growth - A...
- 5. Fidelity International...
- show all
- Top Do-It-Yourself Portfolios
- » agtest1
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » HMH1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Rebecca Corvino Posted at 12:47 p.m. EDT on July 6, 2009 Oil was in the red on Monday, sending stocks and the three major indices lower as well. Bank of America (...
By Fred Fuld Posted at 12:11 p.m. EDT on July 6, 2009 Revenue and earnings surprises can cause stocks to make sharp moves upwards, which in turn can set off a short sq...
By Jonas Elmerraji Posted at 11:07 a.m. EDT on July 6, 2009 As we approach the second week in July, the markets have done a good job of matching the summer heat by keep...
By Stockpickr Staff Posted on July 2, 2009 Developments in the stem cell world are starting to get very interesting. On Tuesday, General Electric (GE) signed an exc...
A. MCD and YUM with no doubt in mind. I am
long both.
A. The only one I own : SLX,
too hard pick a winner out all of them
Here are some stocks that moved up on unusual volume on July 1, 2009. more
Here is a list of some of the biggest stocks that hit 52-week lows as of July 1, 2009. more
Here are some of the largest % gainers from July 1, 2009. more






Comments not available